Search hospitals > North Carolina > Raleigh

WakeMed

Claim this profile
Raleigh, North Carolina 27610
Global Leader in Coronary Artery Disease
Global Leader in Heart Failure
Conducts research for Stroke
Conducts research for Myocardial Ischemia
Conducts research for Coronary Heart Disease
92 reported clinical trials
9 medical researchers
Photo of WakeMed in RaleighPhoto of WakeMed in RaleighPhoto of WakeMed in Raleigh

Summary

WakeMed is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Coronary Artery Disease, Heart Failure, Stroke, Myocardial Ischemia, Coronary Heart Disease and other specialties. WakeMed is involved with conducting 92 clinical trials across 141 conditions. There are 9 research doctors associated with this hospital, such as Judson B Williams, MD, Frances Wood, MD, Stuart Russell, MD, and Saroj Neupane, MD.

Top PIs

Clinical Trials running at WakeMed

Stroke
Kidney Failure
Atrial Fibrillation
Chronic Kidney Disease
Heart Failure
High Blood Pressure
Hemorrhage
Chronic Renal Failure
Renal Disease
Bleeding
Image of trial facility.

Anticoagulation + Antiplatelet Therapy

for Post-Operative Atrial Fibrillation

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

WATCHMAN FLX Pro Device

for Atrial Fibrillation

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Recruiting1 award N/A
Image of trial facility.

Non-Invasive Device

for Traumatic Brain Injury

The purpose of this research, which has been determined as non-significant risk by the central IRB overseeing the study, is to obtain information to help further develop a machine (a medical device) to measure the pressure around the brain from the outside (this pressure is called intracranial pressure or ICP). Monitoring and managing ICP is an important part of care for patients with conditions such as Traumatic Brain Injury (TBI). However, the current way of measuring ICP requires surgery to drill a hole into the skull, and therefore can introduce additional risks such as infections and pain. Recent research has shown it may be possible to measure ICP without needing surgery. This technology is in development, but large amounts of data is required to build these new devices. Through collecting a large database of information from patients who have both the routine surgical device and the research device applied to their head, the research team will work to develop and test an effective and potentially safer way of monitoring patient ICP.
Recruiting1 award N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at WakeMed?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security